Skip to main content
Fig. 1 | Alzheimer's Research & Therapy

Fig. 1

From: Comparative evaluation of clinical and cerebrospinal fluid biomarker characteristics in rapidly and non-rapidly progressive Alzheimer’s disease

Fig. 1

Cerebrospinal fluid biomarkers at baseline. Cerebrospinal fluid biomarker concentrations in diagnostic groups. Comparison of biomarker concentrations of diagnostic groups was performed with Mann–Whitney U tests. Results were corrected by multiple logistic regressions in a second step for the confounders “age at lumbar puncture” and “duration of disease at lumbar puncture.” P-values from regression models are indicated below dot columns. *p-values below significance threshold of 0.05. Bar indicates median. CSF, cerebrospinal fluid; rpAD, rapidly progressive Alzheimer’s disease; Aβ, amyloid beta

Back to article page